Claims
- 1. A transgenic mouse comprising a disruption in a GPCR5-1 gene.
- 2. A transgenic mouse comprising a disruption in a GPCR5-1 gene, wherein there is no native expression of endogenous GPCR5-1 gene.
- 3. The transgenic mouse of claim 2, wherein the disruption is heterozygous.
- 4. The transgenic mouse of claim 2, wherein the disruption is homozygous.
- 5. The transgenic mouse of claim 4, wherein the transgenic mouse exhibits a hyperactivity disorder.
- 6. The transgenic mouse of claim 5, wherein the hyperactivity disorder is characterized by an increase in total distance traveled in an open field test.
- 7. The transgenic mouse of claim 5, wherein the hyperactivity disorder is consistent with a symptom associated with human hyperactivity.
- 8. A method of producing a transgenic mouse comprising a disruption in a GPCR5-1 gene, the method comprising:
(a) providing a murine stem cell comprising a disruption in a GPCR5-1 gene; and (b) introducing the murine stem cell into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a transgenic mouse.
- 9. The transgenic mouse produced by the method of claim 8.
- 10. A targeting construct comprising:
(a) a first polynucleotide sequence homologous to at least a first portion of a GPCR5-1 gene; (b) a second polynucleotide sequence homologous to at least a second portion of a GPCR5-1 gene; and (c) a selectable marker.
- 11. A cell comprising a disruption in a GPCR5-1 gene, the disruption produced using the targeting construct of claim 10.
- 12. A cell derived from the transgenic mouse of claim 2.
- 13. A cell comprising a disruption in a GPCR5-1 gene.
- 14. The cell of claim 13, wherein the cell is a stem cell.
- 15. The cell of claim 14, wherein the stem cell is an embryonic stem cell.
- 16. The cell of claim 15, wherein the embryonic stem cell is a murine cell.
- 17. A method of identifying an agent that modulates a hyperactivity disorder, the method comprising:
(a) contacting a test agent with GPCR5-1 protein; and (b) determining whether the agent modulates GPCR5-1 protein.
- 18. A method of identifying an agent that modulates a hyperactivity disorder, the method comprising:
(a) administering a test agent to an animal exhibiting a hyperactivity disorder; and (b) determining whether the agent modulates the hyperactivity disorder.
- 19. A method of identifying a potential therapeutic agent for the treatment of hyperactivity, the method comprising:
(a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a GPCR5-1 gene; and (b) determining whether the potential therapeutic agent modulates hyperactivity, wherein modulation of hyperactivity identifies a potential therapeutic agent for the treatment of hyperactivity.
- 20. A method of identifying a potential therapeutic agent for the treatment of hyperactivity, the method comprising:
(a) contacting the potential therapeutic agent with GPCR5-1 protein; (b) determining whether the agent modulates GPCR5-1 protein, wherein modulation of GPCR5-1 protein identifies a potential therapeutic agent for the treatment of hyperactivity.
- 21. A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a GPCR5-1 gene, the method comprising:
(a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a GPCR5-1 gene; and (b) evaluating the effects of the agent on the transgenic mouse.
- 22. A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a GPCR5-1 gene, the method comprising:
(a) contacting the potential therapeutic agent with GPCR5-1 protein; (b) evaluating the effects of the agent on the GPCR5-1 protein.
- 23. A method of determining whether an agent modulates GPCR5-1, the method comprising:
(a) providing a first preparation derived from the mouse of claim 2;(b) providing a second preparation derived from a wild-type mouse; (c) contacting a test agent with the first and second preparations; and (d) determining whether the agent modulates the first and second preparations, wherein modulation of the second preparation but not the first preparation indicates that the agent modulates GPCR5-1 receptor.
- 24. A therapeutic agent for treating hyperactivity, wherein the agent modulates GPCR5-1.
- 25. A therapeutic agent for treating hyperactivity, wherein the agent is an agonist of GPCR5-1.
- 26. A pharmaceutical composition comprising a GPCR5-1 gene or GPCR5-1 protein.
- 27. A method of preparing a pharmaceutical composition for a condition associated with a function of GPCR5-1 protein, the method comprising:
(a) identifying a compound that modulates the GPCR5-1 protein; (b) synthesizing the identified compound; and (c) incorporating the compound into a pharmaceutical carrier.
- 28. Phenotypic data associated with a transgenic mouse comprising a disruption in a GPCR5-1 gene, wherein the phenotypic data is in an electronic database.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 60/280,322, filed Mar. 29, 2001, and U.S. Provisional Application No. 60/342,511, filed Dec. 21, 2001, the entire contents of which are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60280322 |
Mar 2001 |
US |
|
60342511 |
Dec 2001 |
US |